Akari Therapeutics Plc
AKTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001541157
No open-market purchases or sales by Akari Therapeutics Plc insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.54M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Akari Therapeutics Plc as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 6
- −14 vs. Q4 2025
- Shares held
- 66.9K
- −4.37M (−98.5%) vs. Q4 2025
- Total value
- $308.2K
- −$972.3K (−75.9%) vs. Q4 2025
- New holders
- 1
- 0 more added
- Sold out
- 15
- 5 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AKTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $1.54M |
| Q1 2026 | 6 | $308.2K |
| Q4 2025 | 21 | $1.29M |
| Q3 2025 | 16 | $1.18M |
| Q2 2025 | 15 | $644.3K |
| Q1 2025 | 11 | $377.3K |
| Q4 2024 | 14 | $393.8K |
| Q3 2024 | 10 | $535.9K |
| Q2 2024 | 10 | $488.1K |
| Q1 2024 | 8 | $326.3K |
| Q4 2023 | 9 | $891.6K |
| Q3 2023 | 8 | $1.19M |
| Q2 2023 | 16 | $1.71M |
| Q1 2023 | 12 | $1.84M |
| Q4 2022 | 15 | $4.19M |
| Q3 2022 | 14 | $6.37M |
| Q2 2022 | 14 | $1.68M |
| Q1 2022 | 11 | $1.89M |
| Q4 2021 | 11 | $2.16M |
| Q3 2021 | 14 | $1.99M |
| Q2 2021 | 12 | $2.27M |
| Q1 2021 | 15 | $3.90M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Akari Therapeutics Plc; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 38,922 | $200.4K | 0.01% | −2,685,044−98.6% | Reduced |
| Cresset Asset Management, LLC | 20,561 | $105.9K | 0.00% | −801,907−97.5% | Reduced |
| IFP Advisors, Inc | 7,431 | $1.81K | 0.00% | +7,431 | New |
| SBI Securities Co., Ltd. | 5 | $26 | 0.00% | −195−97.5% | Reduced |
| Truvestments Capital LLC | 1 | $5 | 0.00% | −49−98.0% | Reduced |
| Morgan Stanley | 1 | $5 | 0.00% | −2−66.7% | Reduced |
| Warberg Asset Management LLC | 0 | $0 | 0.00% | −308,340−100.0% | Sold out |
| Palo Alto Investors LP | 0 | $0 | 0.00% | −146,024−100.0% | Sold out |
| HighTower Advisors, LLC | 0 | $0 | 0.00% | −79,236−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −71,644−100.0% | Sold out |
| SmartHarvest Portfolios, LLC | 0 | $0 | 0.00% | −69,248−100.0% | Sold out |
| CWA Asset Management Group, LLC | 0 | $0 | 0.00% | −55,000−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −49,019−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −32,855−100.0% | Sold out |
| Cerity Partners LLC | 0 | $0 | 0.00% | −23,643−100.0% | Sold out |
| StoneX Group Inc. | 0 | $0 | 0.00% | −21,295−100.0% | Sold out |
| Independent Advisor Alliance | 0 | $0 | 0.00% | −17,075−100.0% | Sold out |
| GWM Advisors LLC | 0 | $0 | 0.00% | −6,800−100.0% | Sold out |
| Accent Capital Management, LLC | 0 | $0 | 0.00% | −5,000−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −410−100.0% | Sold out |
| Cornerstone Planning Group LLC | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| Skyview Financial Group LLC | – | – | – | – | Not filed |